Company Overview and News
It's a perennial favorite, with investors and industry insiders requesting it over and over again. We wanted to provide a simple number that could be referenced and compared. Something like the GDP growth rate, which on its face is a quick look at the economy, but in reality, is a simplified summary of a nuanced subject.
LINEQ ETP.PRC LGCYP LGCYO BBPPQ LNGG VNRR BBEP WPZ ETP VNR LGCY VNRAP VNRBP VNRCP BBEPQ EEP PAA BBEPP LINE
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LINEQ LNGG XOM LINE
HOUSTON, April 18, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTC:LNGG) (“LINN” or the “Company”) provides a strategic update on the previously announced separation, announces new leadership and schedules its first quarter 2018 earnings conference call.
LINEQ LNGG LINE
Natural Gas Liquids (NGLs) Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the Cost Structure, Sales Revenue, Sales Volume, Gross Margin, market share and growth rate.
XOM LNGG CHKVP DVN BP RRL RDSB RDSA CHKDH CHKVZ SWTF CHKDG SU COP CHKDJ CHKDP SFY RYDAF CHK.PRD SU LINEQ CKRGZ RDS.B RDS.A SM SBOW RRS BP.A BP.B RGRLF CHKWZ RRC BP RGRYY CNQ CHK.WI CHK RYDBF STOHF BPAQF LINE STO
20h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET